Turning Point ROS1/TRK Inhibitor Repotrectinib Could Stand Out On Durability

 
• By Alaric DeArment
  
Turning Point's repotrectinib showed a high level of durability of response • Source: Alamy

More from Anticancer

More from Therapy Areas